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Quality of lifeAbstract Background: Chronic obstructive pulmonary disease (COPD) is associated with skeletal
muscle dysfunction. This study aimed to evaluate effectiveness of inspiratory muscle training (IMT)
as a part of exercise training in COPD patients.
Methods: Sixty male patients were assigned to 3 groups; twenty in each group. In addition to
medical treatment given for all patients; patients in group A received peripheral muscles exercise
training plus IMT at an intensity that increased from 30% to 60% of their maximal inspiratory
pressure (PImax). Patients in group B received peripheral muscle exercise training alone, and in
group C; they received no training. All patients underwent clinical evaluation, chest X-ray, electro-
cardiogram, body mass index, and spirometry. Outcome measures in the form of respiratory muscle
strength [PImax, maximal expiratory pressure (PEmax)], dyspnea, exercise performance (six minutes
walk test) and quality of life [BODE index and St. George’s Respiratory questionnaire for COPD
patients (SGRQ-C)] were carried out at study entry, after 4 and 8 weeks.
Results: IMT plus peripheral muscle exercise training led to a signiﬁcant improvement in PImax,
PEmax, and 6-min walking distance (6MWD) compared to peripheral muscle exercise training alone.
Both IMT plus peripheral muscle exercise training and peripheral muscle exercise training alone
improved dyspnea, BODE index and SGRQ-C without signiﬁcant differences between 2 groups.disease;
nitiative
portant
Q-C, St
oo.com
rculosis.
42 A.S. Elmorsi et al.Conclusion: For PImax, PEmax, and 6MWD; IMT provides additional beneﬁts to peripheral mus-
cle exercise training in COPD patients. However, this did not translate into additional improvement
in dyspnea and quality of life compared with what is achieved by peripheral muscle exercise alone.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a multisys-
tem disease affecting the skeletal muscle both peripheral and
respiratory [1,2]. Weakness of respiratory muscle in COPD
patients leads to hypercapnia, dyspnea, and decreased exercise
capacity [3]. In COPD; inspiratory muscle training (IMT) as a
monotherapy improves inspiratory muscle strength, exercise
capacity, and decreases dyspnea [3,4]. However, the value of
addition of IMT to a general exercise training program is still
questionable [5,6]. The aim of this work was to evaluate the
effectiveness of IMT as a part of exercise training program
in patients with COPD.Methods
This prospective comparative interventional study was carried
out at Chest Medicine and Rheumatology and Rehabilitation
Department; Mansoura University Hospital; Egypt. All sub-
jects enrolled from October, 2011 to April, 2014. Ethics
approval has been obtained from Medical Research Ethics
Committee in July, 19th, 2011; Mansoura University. The pro-
tocol for this work was published on ClinicalTrials.gov (iden-
tiﬁer: NCT02257463).
Ninety-four male patients between 45 and 65 years old with
moderate to very severe COPD were recruited in this study.
The severity was classiﬁed according to Global Initiative for
Chronic Obstructive Lung Disease (GOLD) into stage II,
III, and IV based on post bronchodilator forced expiratory
volume in one second (FEV1) values in patients with FEV1/
forced vital capacity (FVC) < 0.70 [7]. In addition to theo-
phylline, patients also received medications in the form of
either inhaled long acting bronchodilators (LABD) or com-
bined LABD and inhaled steroids according to GOLD recom-
mendations [7]. All patients were exsmokers, had a stable
clinical condition at the time of study and with low maximal
inspiratory pressure (PImax) [<60 cm H2O] [8]. Patients with
signiﬁcant reversibility following bronchodilation deﬁned as
an increase in FEV1 of more than 12% and 200 ml from the
pre-bronchodilator value [9], those with unstable cardiac dis-
eases, uncontrolled hypertension, recent pneumothorax, recent
abdominal or thoracic surgery, known progressive neuromus-
cular disorders, advanced liver diseases, or renal impairment,
known connective tissue diseases, or signiﬁcant endocrinal
abnormalities were excluded from the study.
While 34 patients dropped out from the study, 60 patients
completed the study and were classiﬁed into 3 groups. Group
A (study group) included 20 patients treated with pharmaco-
logical therapy, peripheral muscle exercise training, and
IMT. Group B (control positive group) included 20 patients
treated with pharmacological therapy, peripheral muscle
exercise training without IMT; and 20 patients were enrolledinto group C (control negative group). They were treated only
with pharmacological therapy without any kind of pulmonary
rehabilitation.
Patients in group A and group B were chosen randomly.
Those with odd numbers were classiﬁed to be in group A while
those with even numbers were classiﬁed to be in group B. For
group C and to decrease the drop out ratio, patients from dis-
tant localities who found difﬁculty in adherence with the study
protocol from the start because of the economic state and
transportation issues were classiﬁed in this group to ensure
only one monthly visit. We also chose male patients as the dis-
ease is not common in females in our locality, and to avoid
gender-associated differences in the response to pulmonary
rehabilitation.
All patients underwent baseline assessment including thor-
ough history taking, clinical examination, plain chest X-ray,
electrocardiogram, and body mass index (BMI). Patients were
then evaluated before the study, after 4 and 8 weeks (except for
reversibility after bronchodilators) using spirometry, respira-
tory muscle strength device, six minute walk test (6MWT),
dyspnea grading, BODE index, and St. George’s Respiratory
questionnaire for COPD patients (SGRQ-C). Spirometry was
performed to measure FEV1, FVC, FEV1/FVC ratio, and
reversibility after bronchodilators using smart pft lab, Medical
Equipment Europe GmbH, Germany according to the stan-
dardized protocol [10]. Respiratory muscle strength was evalu-
ated using a handheld mouth pressure meter (Micro MPM;
Micro Medical, UK) with measuring PImax and maximal expi-
ratory pressure (PEmax) as previously described [11]. Six minute
walk test (6MWT) was conducted according to the procedures
recommended by the American Thoracic Society [12]. Grading
of dyspnea was performed using the modiﬁed Medical
Research Council (mMRC) [13]. With recording BMI, the
FEV1, mMRC dyspnea scale, and the six minutes walk dis-
tance (6MWD); BODE index was calculated [14]. Finally,
assessment of quality of life using St. George’s Respiratory
questionnaire for COPD patients (SGRQ-C) was done.[15].
Training protocol
1. Peripheral exercise trainingWe followed The Pulmonary
Rehabilitation Toolkit on behalf of The Australian Lung
Foundation [16]. The program was conducted following a
schedule of 24 visits in the 8 week period. Patients in group
A and group B were subjected to a combination of lower
limb endurance training using treadmill walking, upper
limb endurance training with a combination of arm raise
and arms together, upper limb strength training using hand
weights for biceps and triceps, and lower limb strength
training using straight leg raise.
2. Inspiratory muscle training (IMT)All subjects in group A
only were trained daily, six times a week; each session con-
sisted of 30 min, for 2 months using a threshold inspiratory
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Healthscan, New Jersey, NJ, USA). Patients started breath-
ing at a resistance that required the generation of 30% of
their PImax for one week. The load was then increased incre-
mentally, 5–10%, to reach a generation of 60% of their
PImax at the end of the ﬁrst month. Speciﬁc IMT was then
continued at 60% of their PImax adjusted weekly to the new
PImax achieved.
Statistical analyses
The statistical analysis of data was done using SPSS program
version 16.0. For mMRC dyspnea scale; data were expressed
as median (minimum–maximum); non-parametric two-
related-samples test (Wilcoxon type) was used to compare
the results in the same group. Kruskal–Wallis H test was used
to compare the results between the three groups; andTable 1 Patients’ characteristics, and baseline spirometry.
Group A (n= 20)
Age (Years) (mean ± SD) 57.20 ± 5.08
Smoking index (P-Y) (mean ± SD) 55.60 ± 19.63
BMI (kg/m2) (mean ± SD) 24.98 ± 5.16
COPD group [N (%)]
GOLD II 7 (35%)
GOLD III 7 (35%)
GOLD IV 6 (30%)
MVV (% predicted) (mean ± SD) 40.17 ± 10.96
Base line spirometry (mean ± SD)
FEV1 (% predicted) 41.77 ± 17.76
FVC (% predicted) 65.22 ± 22.16
FEV1/FVC (%) 50.40 ± 9.85
P-Y: pack-year index; BMI: body mass index; COPD: chronic obstructive
Lung Disease; FEV1: forced expiratory volume in one second; FVC: forc
Table 2 Baseline values and changes in PImax, PEmax and 6MWD a
Baseline Week 4
PImax (cm H2O)
Group A 51.05 ± 3.22 58.80 ± 3.89
Group B 52.95 ± 4.73 59.00 ± 5.21
Group C 51.50 ± 4.76 52.40 ± 4.76
p value 0.351 0.000
PEmax (cm H2O)
Group A 84.20 ± 7.67 94.30 ± 8.15
Group B 87.50 ± 7.12 95.25 ± 8.15
Group C 86.55 ± 8.42 87.60 ± 8.53
p value 0.389 0.009
6MWD (m)
Group A 296.65 ± 28.12 335.95 ± 29.24
Group B 311.60 ± 46.18 337.20 ± 45.81
Group C 289.25 ± 39.54 292.60 ± 44.07
p value 0.186 0.001
PImax: maximal inspiratory pressure; PEmax: maximal expiratory pressure;
p* value: p value within the group at 4 weeks in comparison to 0 week; p#
values are expressed as mean ± SD; number of patients in each group =
 Signiﬁcant from group C.
e Signiﬁcant from group B.two-independent-samples tests (Mann–Whitney U type) were
used to compare the results between the two groups. For data
with normal distribution; descriptive statistics were used to cal-
culate mean ± standard deviation (SD); paired sample t-test
was used to compare the results in the same group. A one
way ANOVA test was used to compare the results between
the three groups; and post hoc Bonferroni test was used to
compare the results between the two groups. Statistical signif-
icance was deﬁned as p value less than 0.05.
Results
Thirty-four patients dropped out of the study for the following
reasons: acute exacerbation of COPD with hospitalization
(n= 2), facial burn (n= 1), inability to perform training
(n= 1), late diagnosis of knee osteoarthritis (n= 1), diabetic
retinopathy (n= 1), economic and social problems (n= 6),
or withdrawal from the study without known reasonsGroup B (n= 20) Group C (n= 20) p value
55.70 ± 6.12 56.80 ± 4.95 0.664
58.30 ± 28.79 44.95 ± 15.38 0.137
25.47 ± 4.90 27.61 ± 4.69 0.207
5 (25%) 5 (25%) 0.773
10 (50%) 11 (55%)
5 (25%) 4 (20%)
39.42 ± 10.43 38.16 ± 8.86 0.817
38.04 ± 14.05 41.01 ± 12.17 0.704
63.65 ± 17.98 60.51 ± 13.78 0.711
48.35 ± 9.68 53.25 ± 8.60 0.262
pulmonary disease; GOLD: Global Initiative for Chronic Obstructive
ed vital capacity; MVV: maximal voluntary ventilation.
t 4 and 8 weeks.
Week 8 p* value p# value
70.75 ± 3.34,e 0.000 0.000
65.60 ± 5.09 0.000 0.000
53.20 ± 4.95 0.001 0.000
0.000
107.70 ± 10.28 0.000 0.000
105.60 ± 9.18 0.000 0.000
88.95 ± 8.66 0.000 0.000
0.000
387.20 ± 32.87 0.000 0.000
372.45 ± 45.37 0.000 0.000
300.70 ± 42.47 0.295 0.000
0.000
6MWD: 6-min walking distance; p value: p value between the groups;
value: p value within the group at 8 weeks in comparison to 0 week;
20.
Table 3 Median differences for PImax, PEmax and 6MWD at 4 and 8 weeks.
Group A Group B Group C p value
PImax median diﬀerence at 4 weeks 8 (5–11)
e, 6 (4–8) 1 (1–3) 0.000
PImax median diﬀerence at 8 weeks 20 (15–23)
e, 13 (9–15) 1.5 (1–3) 0.000
PEmax median diﬀerence at 4 weeks 10 (7–17)
e, 7.5 (4–13) 1 (1–3) 0.000
PEmax median diﬀerence at 8 weeks 23 (16–38)
e, 19 (7–24) 2 (1–4) 0.000
6MWD median diﬀerence at 4 weeks 37 (28–66)e, 25 (13–38) 11 (24–18) 0.000
6MWD median diﬀerence at 8 weeks 89.5 (66–121)e, 61 (45–84) 10 (7–36) 0.000
Values are expressed as median (mim-max); number of patients in each group = 20.
 Signiﬁcant from group C.
e Signiﬁcant from group B.
Table 4 Baseline and changes in mMRC dyspnea scale at 4
and 8 weeks.
Baseline Week 4 Week 8 p* value p# value
Group A 3 (2–3) 2 (2–3) 1.5 (1–2) 0.001 0.000
Group B 3 (2–3) 2 (2–3) 2 (1–2) 0.002 0.000
Group C 3 (2–3) 3 (2–3) 3 (2–3) 0.317 0.317
p value 0.151 0.024 0.000
mMRC: modiﬁed Medical Research Council; p value: p value
between the groups; p* value: p value within the group at 4 weeks in
comparison to 0 week; p# value: p value within the group at 8 weeks
in comparison to 0 week; number of patients in each group = 20.
 Signiﬁcant from group C.
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group. The general characteristics of patients are described
in Table 1. The three groups were well-matched as regard
age, smoking index, BMI, GOLD staging, and spirometric
measures with no signiﬁcant difference for any variable
between groups.
There were no signiﬁcant differences among the three
groups at baseline for any of the outcomes (Tables 2, 4 and 5).
PImax, PEmax and 6MWD increased signiﬁcantly in all groups
with signiﬁcant differences between group A and group B
compared to group C (Table 2). Also, there were signiﬁcant
differences between group A and group B in these 3 outcomes
(Table 3).Table 5 Baseline and. changes in BODE index and SGRQ-C total
Baseline Week 4
BODE index
Group A 5.15 ± 1.57 4.30 ± 1.87
Group B 5.20 ± 1.24 4.60 ± 1.31
Group C 4.95 ± 1.28 5.05 ± 1.23
p value 0.830 0.289
SGRQ-C total score
GroupA 81.86 ± 10.05 65.22 ± 10.90
Group B 80.69 ± 12.08 64.36 ± 11.62
Group C 76.63 ± 10.08 78.11 ± 10.17
p value 0.281 0.000
SGRQ-C: St. George’s Respiratory questionnaire for COPD patients; p va
4 weeks in comparison to 0 week; p# value: p value within the group at 8
number of patients in each group = 20.
 Signiﬁcant from group C.The mMRC dyspnea scale (Table 4), BODE index and
SGRQ-C total score (Table 5) improved signiﬁcantly in group
A and group B but not in group C, with no signiﬁcant differ-
ences between group A and group B in mMRC dyspnea scale
(Table 4), BODE index and SGRQ-C total score (Tables 5).
Discussion
In this study; PImax showed a statistically signiﬁcant improve-
ment in all groups. However; there was a statistically signiﬁ-
cant improvement in group A in comparison to group B and
group C. These ﬁndings were in agreement with previously
published studies on patients with COPD who received com-
bined IMT plus general exercise reconditioning (GER) versus
patients who received GER alone [17,18]. In other studies;
however; PImax improved only in patients that received addi-
tional IMT beside GER [19–22]. On the other hand; various
studies on general exercise training alone in patients with
COPD found improvement in PImax after training [23,24].
Addition of IMT to GER results in signiﬁcant improve-
ments in inspiratory muscle strength than GER alone. IMT
is known to improve pulmonary oxygen uptake kinetics [5]
Furthermore, Ramirez-Sarmiento et al. [25] found structural
adaptations in external intercostal muscles following IMT in
patients with COPD. Therefore; IMT seems to have speciﬁc
physiological effects on respiratory muscles. General exercise
training alone can also improve PImax as during the course of
training; if the respiratory muscles become sufﬁciently over-
loaded, substantial structural and functional adaptation willscore at 4 and 8 weeks.
Week 8 p* value p# value
3.05 ± 1.61 0.000 0.000
3.50 ± 1.36 0.000 0.000
4.90 ± 1.25 0.330 0.577
0.000
49.19 ± 10.72 0.000 0.000
52.99 ± 11.11 0.000 0.000
81.12 ± 8.49 0.174 0.000
0.000
lue: p value between the groups; p* value: p value within the group at
weeks in comparison to 0 week; values are expressed as mean ± SD;
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the studies may be explained by the difference in patients’
characteristics, number of patients involved in the studies, dif-
ferent training protocol, or different training intensities.
We also noticed that the mean PImax in group C increased
signiﬁcantly (p< 0.001). This increase, however; did not
translate into clinical improvement as regards dyspnea,
6MWD and quality of life. This could be attributed to the
learning effect, theophylline, bronchodilator therapy or
improved patients’ effort with repetition of the test.
PEmax also showed a statistically signiﬁcant improvement in
group A and group B in comparison to group C with a signiﬁ-
cant difference in improvement between group A compared to
group B.Most of the previous studies did not evaluate the effect
of training on PEmax. O’Donnell et al. [23] showed a signiﬁcant
increase in PEmax in response to exercise despite they did not
use IMT in their protocol. On the other side, Larson et al. [21]
did not demonstrate a change in PEmax in their study in any of
the four studied groups (IMT alone, GER alone, combined
IMT and GER, and health education). However; in that study;
PImax did not also improve in the group that received general
exercise training only. These differences may be attributed to
different populations studied, different protocols or intensities.
In this study; 6MWD showed a statistically signiﬁcant
improvement in group A and group B compared to group C.
Also; the improvement in 6MWD in group A was statistically
signiﬁcant from group B. These results were in agreement with
many authors who found a signiﬁcant increase in the group
that received additional IMT beside GER [17–19]. On the
other hand, our results were in disagreement with other
authors who found a signiﬁcant improvement in walking dis-
tance in the group that received combined IMT and GER
and in the group received GER alone with no statistically sig-
niﬁcant difference between the groups [27–29]. The difference
in the results may be attributed to difference in training dura-
tion, intensity, protocols among the studies, or patients’ char-
acteristics. For example; Dekhuijzen and colleagues [17] beside
using higher intensity for IMT (70% of patients’ PImax) and
longer duration (10 weeks); they also selected patients with
ventilatory limitation that was deﬁned by the authors as a nor-
mal resting arterial partial pressure of carbon dioxide that rose
during progressive exercise. This may indicate an insufﬁciency
of the respiratory muscles to maintain adequate ventilation
during the higher metabolic rate of exercise.
In group C, although the mean 6MWD increased signiﬁ-
cantly, it was not translated into clinical improvement in dys-
pnea or quality of life as Holland et al. deﬁned minimal clinical
importance difference (MCID) of 25 m [30]. The improvement
in this group may be due to optimization of pharmacotherapy
during the study, or because patients acquired more conﬁdence
in performing the test.
In this study;mMRCdyspnea scale showed a statistically sig-
niﬁcant improvement in group A and group B but not in group
C, with no statistically signiﬁcant difference between group A
and group B. While our results were in agreement with studies
conducted by Larson et al. [21], Berry et al. [28], and Mador
et al. [29]; however; Sykes and Hang [18], Magadle et al. [22],
andWeiner et al. [31] found a signiﬁcant decrease in the percep-
tion of dyspnea in the combined IMTandGERgroup but not in
the group that received GER alone. Again, this difference may
be attributed to difference in training duration, intensity, proto-
cols among the studies, or patients’ characteristics.After training; oxidative capacity and skeletal muscle efﬁ-
ciency improve. This can lead to a reduction in ventilatory
requirement for a given submaximal work rate; which by its
turn may reduce dynamic hyperinﬂation, thereby adding to
the reduction in exertional dyspnea [32,33]. Exercise programs
can also result in desensitization to dyspnea through the
antidepressant effect of exercise, social interaction, and dis-
traction from dyspneic sensations that occur during exercise
with a group of patients who have the same condition [34,35].
In this work, there was a statistically signiﬁcant change in
the BODE index at 4 and 8 weeks in group A and group B
but not in the group C with no signiﬁcant difference between
group A and group B in the BODE index after 8 weeks. To
our knowledge, studies that compared combined IMT and
GER versus GER alone did not evaluate the changes in BODE
index. However, some studies on pulmonary rehabilitation
demonstrated the effect of rehabilitation on the BODE index.
Cote and Celli [14] found an improvement in the BODE index
of 19% in the group that received pulmonary rehabilitation.
Many other studies found signiﬁcant reductions in BODE
index after training [36–39].
Cote and Celli [14] had deﬁned a one unit change in the
BODE index as clinically signiﬁcant as a change in any of its
components is important to inﬂuence clinical outcomes. They
also found that the change in the BODE index after pulmonary
rehabilitation provides valuable prognostic information. Bis-
cione et al. [36] and Kosmas et al. [38] found that the BODE
index could be a useful indicator of the quality of life.
In our study; SGRQ-C total score showed a statistically sig-
niﬁcant improvement in group A and group B but not in the
group C with no statistically signiﬁcant difference between
group A and group B. This was in agreement with studies con-
ducted by Dekhuijzen et al. [17] and Mador et al. [29]. How-
ever, our results were in disagreement with Sykes and Hang
[18] and Magadle et al. [22] who found a greater decrease in
patients that received combined IMT and GER. This differ-
ence may be explained by the difference in patient characteris-
tics, number of patients involved in the study, different
training protocol, or different training intensities.
In conclusion; IMT provides additional beneﬁts to COPD
patients undergoing peripheral muscle exercise training as
regards respiratory muscle strength and exercise capacity.
However, this improvement did not translate into additional
improvement in dyspnea and quality of life compared with
what is achieved by peripheral muscle exercise training alone.
Further studies with different IMT intensities and longer dura-
tion are recommended.
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